SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its recent earnings report, where the company exceeded revenue and EPS expectations, yet the stock experienced a notable after-hours decline. This unexpected dip, despite positive top and bottom-line results, has fueled community discussions ranging from claims of market manipulation to strong conviction among long-term investors buying the dip. Investors are actively debating the implications of the company's guidance, including its Q1 EPS forecast and projected doubling of ad revenue, alongside ongoing discussions about the strategic acquisition of Warner Bros. Discovery assets.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as community discussion surges following CEO Ryan Cohen's significant additional share purchases, fueling speculation that the stock's bottom is in and a new 'meme season' could be on the horizon. Investors are actively debating a potential short squeeze and eagerly awaiting any communication from "Roaring Kitty," while noting the stock's notable resilience amidst broader market weakness.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending following compelling Phase 1 clinical trial data for its oral drug soquelitinib in atopic dermatitis, which demonstrated strong efficacy and a favorable safety profile, driving the stock to significant gains. Community discussion highlights both excitement for its potential as a best-in-class treatment for a large market and concerns surrounding a recently announced stock offering, with opinions split on whether it's a strategic funding move or a precursor to dilution. Investors are keenly watching the long-term implications of this early-stage therapeutic and its market validation.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant attention due to a highly positive FDA update for its ANKTIVA bladder cancer treatment, as the agency will not require new clinical trials for its resubmission, greatly de-risking the approval pathway. This development, combined with high short interest and massive trading volume, is driving strong community conviction around a potential short squeeze and the therapy's broader "cure for cancer" implications across multiple indications, even as the stock demonstrates notable resilience in a challenging market.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as the market reacts to escalating geopolitical tensions stemming from President Trump's aggressive rhetoric regarding Greenland and proposed tariffs on European allies. Community discussions reflect widespread anxiety over potential economic instability and a significant market sell-off, with many anticipating continued downside amid concerns about international relations and a carry trade unwind.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group is trending following its announcement of acquiring a wine authentication and trading business, coupled with a recent public offering and a positive profit outlook. This has fueled sharp price volatility, dividing the community between those calling it a "Chinese pump and dump" and others who view the dips as a buying opportunity in this low-float stock. The intense discussion reflects strong speculative interest and reactions to recent corporate developments.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending due to its planned split into two independent companies by 2026 and recent analyst downgrades, sparking an intense community debate. Many investors view the stock as deeply undervalued with an attractive dividend yield, believing current prices present a significant buying opportunity amidst accusations of market manipulation. The community largely anticipates value creation from the corporate separation, positioning KHC as a defensive play during broader market uncertainty.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid an intensifying bidding war, as Netflix recently revised its acquisition offer to all-cash for its studio and streaming assets. This move aims to counter Paramount Skydance's rival all-cash bid, though WBD's board continues to favor Netflix's proposal, citing concerns over Paramount's financing and the complexities of a potential breakup, leaving shareholders debating the superior path forward.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies Global is trending following a strategic private placement with Medtronic and the enrollment of the first patients in its pivotal PARADIGM trial for the DurAVR heart valve. This dual news has ignited intense community discussion, with many viewing Medtronic's involvement as a strong validation and anticipating significant appreciation. However, others express concern over potential dilution from the associated public offering despite the positive developments.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid news of new contracts with the U.S. Army for AI-driven logistics and the Department of Health and Human Services to establish a unified national health-data platform. This recent federal traction, combined with a deepened Microsoft partnership and high short interest, is driving intense debate between those anticipating a major turnaround and skeptics pointing to persistent revenue challenges and insider selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified in the patient who died, the FDA said.&nbsp;</li><li>The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma.</li><li>The agency noted that neutralizing antibodies were not reported in clinical trials.</li></ul>The U.S. Food and Drug Administration (FDA) said on Friday that it is investigating the death of a patient treated with Adzynma.Adzynma, a man-made enzyme therapy manufactured by Takeda Pharmaceuticals (TAK), is approved for adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw-Schulman syndrome. It is a rare inherited disorder characterized by a severe deficiency of the ADAMTS13 enzyme.The death of a pediatric cTTP patient appears to be related to Adzynma, the FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-death-due-neutralizing-antibodies-adamts13-following-adzynma-treatment-congenital">said</a>.<h2 class="st-heading-2">Findings And Further Probe</h2>Before starting Adzynma treatment, the patient had severe allergic reactions to fresh frozen plasma, the FDA noted. After about 10 months of starting treatment with Adzynma, the presence of neutralizing antibodies was identified.However, the agency also noted that current assays cannot differentiate the neutralizing antibodies to man-made enzyme therapy from the neutralizing antibodies to the body’s own enzymes. The agency also added that it has received other reports of neutralizing antibodies in patients treated with the drug since approval.The FDA is now investigating the risk of development of neutralizing antibodies with serious, including life-threatening or fatal, outcomes following treatment with Adzynma. The agency noted that neutralizing antibodies were not reported in clinical trials and that the current labeling does not include the risk of serious and fatal outcomes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TAK stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/TAK">TAK stock</a> has gained 8% this year and about 7% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-obesity-drug-patients-granted-compensation-in-denmark-over-rare-eye-disease-linked-to-wegovy-ozempic/cLPMqfwREOY">Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Takeda Pharmaceutical Company, building exterior with company sign, 500 Kendall Street, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies

 The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said. 

Equity

 The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said. 


Retail sentiment around Anheuser-Busch InBev (ABI),&nbsp;the maker of Budweiser and Corona beers, ticked higher, even as a weak quarterly report sent its shares sliding on Thursday.<a href="https://stocktwits.com/symbol/BUD">BUD's U.S.-listed shares</a> dropped over 13%&nbsp;in the previous session, marking their worst day in over five years.On Stocktwits, retail sentiment&nbsp;shifted to 'extremely bullish' by early Friday, up from 'bullish' the day before, as traders&nbsp;viewed the slide as an overreaction and saw it as a buying opportunity. Message volume for BUD rose 1,200% in the past 24-hour period, among the highest for a consumer stock.<figure class="image"><img style="aspect-ratio:1256/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_12_48_05_PM_png_fd95800c98.webp" alt="Screenshot 2025-08-01 at 12.48.05 PM.png" width="1256" height="156"><figcaption>BUD sentiment and message volume as of August 1 | Source: Stocktwits</figcaption></figure>"Not a fan of the company, but this drop is a bit unjustified," said one user<stembedurl>https://stocktwits.com/Reddiot/message/623258303</stembedurl>Another said: "$BUD Buying dat dip, 10% discount? Thank you!" A third user shared a technical chart showing the stock hitting a key long-term support level.<stembedurl>https://stocktwits.com/stocksailor23/message/623228047</stembedurl><stembedurl>https://stocktwits.com/theoptionsplug/message/623173574</stembedurl>AB InBev said revenue grew 3% organically in the second quarter, below market expectations of 3.2% growth. Organic sales volumes, however, were down 1.9%,&nbsp;primarily due to weak sales in Brazil and China, marking the&nbsp;ninth consecutive quarter of declining beer sales.&nbsp;That was significantly below the 0.3% decline analysts had expected.Organic operating profit increased by 6.5%, ahead of analysts' forecasts of 5.7%.The world's largest brewer also reported weaker-than-expected volumes in Europe and the Middle East,&nbsp;which led to disappointment in all regions except North America.A rebound in the home market comes even as beer demand softens in the region. Bank of America has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bof-a-downgrades-miller-lite-brewer-molson-coors-amid-softness-in-us-beer-sales/chmZESFRReS">predicted</a> that U.S. beer volumes will shrink by 4% next year, steeper than its earlier prediction of 1% decline.In early July, AB InBev&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/budweiser-maker-ab-inbev-plans-300m-investment-to-expand-us-production/chi8fifRbZd">announced</a> plans to invest $300 million in its U.S. manufacturing operations this year, aligning with the Trump administration's broader push for domestic production.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/Starbucks-china-operations-jd-tencent-kkr-among-potential-investors/chr3YU9RdGt">Starbucks China Operations: JD, Tencent, KKR Among Potential Investors To Submit Bids - Report</a>

In this photo illustration, Budweiser beer bottles are seen displayed. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Budweiser Maker’s Stock Gets Crushed After Q2 Gloom — Retail Traders Feel 'Drop Is A Bit Unjustified'

U.S.-listed shares of the world's largest brewer marked their worst day in over five years after the company missed revenue and volume estimates.

Anheuser-Busch InBev (BUD) on Monday announced plans to invest $300 million in its U.S. manufacturing operations this year, aligning with the Trump administration's broader push for domestic production.As part of the investment, the brewer of the popular Budweiser beer will also set up a new plant in Columbus, Ohio."Anheuser-Busch has been a shining example of what 'Made in America' means, and their latest investment of $300 million builds on their longtime commitment to grow our workforce and expand U.S. manufacturing," U.S. Labor Secretary Lori Chavez-DeRemer said, according to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.anheuser-busch.com/newsroom/anheuser-busch-announces-new-300-million-investment-in-manufacturing-operations-across-the-US">statement</a> from the company on Monday.The company earlier stated it was increasing investment in core brands like Budweiser and focusing more on driving at-home consumption, as spending in venues like bars continues to face pressure.Anheuser-Busch is originally an American company, founded in St. Louis, Missouri, which remains the home of its U.S. operations.Anheuser-Busch and a Belgian-Brazilian beverage conglomerate InBev merged in 2008 to form Anheuser-Busch InBev or AB InBev.On Stocktwits, the retail sentiment turned to 'bullish' from 'neutral' the previous day.<figure class="image"><img style="aspect-ratio:568/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_1_00_47_PM_png_61e53222de.webp" alt="Screenshot 2025-05-13 at 1.00.47 PM.png" width="568" height="62"><figcaption>BUD sentiment and message volume as of May 12 | Source: Stocktwits</figcaption></figure>A bullish user said they were "all in on $BUD" because of its global presence and partnerships with key events, including the World Cup.<stembedurl>https://stocktwits.com/bullbearpro/message/614331283</stembedurl>The company's U.S.-listed shares are up 32.4% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Budweiser Maker AB InBev Plans $300M Investment To Expand US Production: Retail Turns Bullish

As part of the plan, the company will also open a new plant in Ohio.

Tidal Trust I - Adasina Social Justice All Cap Global ETF

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

JSTC
Tidal ETF Trust - Adasina Social Justice All Cap Global ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest JSTC News

JSTCTidal ETF Trust - Adasina Social Justice All Cap Global ETF